Cantor Fitzgerald Reiterates Overweight on BridgeBio Pharma, Maintains $70 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on BridgeBio Pharma (NASDAQ:BBIO) and maintained a $70 price target.
May 28, 2024 | 2:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on BridgeBio Pharma (NASDAQ:BBIO) and maintained a $70 price target.
The reiteration of an Overweight rating and a high price target of $70 by a reputable analyst is likely to positively impact the stock price of BridgeBio Pharma in the short term. This indicates strong confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100